Jefferies Financial Group Inc. Purchases New Shares in KalVista Pharmaceuticals, Inc. $KALV

Jefferies Financial Group Inc. purchased a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the third quarter, Holdings Channel.com reports. The firm purchased 286,875 shares of the specialty pharmaceutical company’s stock, valued at approximately $3,494,000.

Other hedge funds also recently bought and sold shares of the company. BNP Paribas Financial Markets boosted its holdings in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the period. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $57,000. KLP Kapitalforvaltning AS purchased a new position in shares of KalVista Pharmaceuticals in the third quarter worth approximately $63,000. Virtus Investment Advisers LLC purchased a new stake in shares of KalVista Pharmaceuticals in the 2nd quarter valued at approximately $81,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of KalVista Pharmaceuticals by 816.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 7,180 shares in the last quarter.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,767 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the transaction, the chief financial officer directly owned 13,762 shares of the company’s stock, valued at $214,274.34. This represents a 11.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,693 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $16.08, for a total value of $107,623.44. Following the sale, the chief executive officer directly owned 451,815 shares of the company’s stock, valued at $7,265,185.20. This trade represents a 1.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 33,378 shares of company stock worth $522,290 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on KALV shares. Citizens Jmp decreased their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Needham & Company LLC upped their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $29.40.

KalVista Pharmaceuticals Trading Up 6.6%

KalVista Pharmaceuticals stock opened at $18.44 on Wednesday. The company’s fifty day simple moving average is $15.66 and its 200-day simple moving average is $14.19. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.23 and a 12 month high of $19.00. The stock has a market cap of $932.14 million, a P/E ratio of -4.67 and a beta of -0.35.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.